Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2
about
Flavivirus modulation of cellular metabolismRecent advances in understanding dengueDengue: Moving from Current Standard of Care to State-of-the-Art TreatmentDengue: an update on treatment optionsAntiviral effect of compounds derived from the seeds of Mammea americana and Tabernaemontana cymosa on Dengue and Chikungunya virus infectionsBroad-spectrum agents for flaviviral infections: dengue, Zika and beyondCurrent Status of Dengue Therapeutics Research and Development.Coupling of replication and assembly in flaviviruses.Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library.DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target.Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses.Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled TrialPotential chemotherapeutic targets for Japanese encephalitis: current status of antiviral drug development and future challenges.Differential virulence of camel Trypanosoma evansi isolates in mice.Biochemistry and Molecular Biology of Flaviviruses.Deconvolution of pro- and antiviral genomic responses in Zika virus-infected and bystander macrophagesRepeated infections of dengue (serotype DENV-2) in lung cells of BALB/c mice lead to severe histopathological consequencesThe Role of Host Cholesterol During Flavivirus Infection
P2860
Q24575425-36164B15-8D87-4007-8220-C2AAC4DB5B7CQ26766156-93499AE7-76A1-4373-A5AB-997002FC0A31Q27010609-F5B435CA-5114-4E4D-A280-DCC7077B599FQ28085044-31E2C3AF-211F-42B6-A93D-C2FE60EF2769Q28584386-457F5722-7EE1-4FA4-9441-3DB5F671CEAAQ29994527-6A842AAF-855E-44EC-B41C-5C1FF9AF4809Q33552896-7CB948BF-EC7B-4A42-9FDF-C383DB32486DQ34716805-3E941637-F133-4F15-8FED-8D01EAC2758CQ36210865-C4C883C8-2A40-4D4B-B04D-1FADBEDE6362Q36338285-66AD5CFA-FB35-4A3E-9A7B-B47DE59C08BFQ36425870-B516177F-F450-4E1D-9C7C-10C421E9BE76Q36497872-D668F717-FC58-456C-8DE3-524A0525BB68Q38544126-626A406D-976E-48C8-84ED-35BED84FDC95Q52707467-55195315-9D34-4A4F-8F73-5231C4020E5CQ55277816-17F2CB9B-F28F-4C26-BC46-6E5ADDC914AEQ58749402-37569F32-D461-47B3-AE90-02164E67750CQ58949641-23FDA6CC-7773-447F-88D7-7AB23DD7D06BQ59132140-EF1FD076-C6B0-4CF2-899E-070A48CBF535
P2860
Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Lovastatin delays infection an ...... d with dengue virus serotype 2
@ast
Lovastatin delays infection an ...... d with dengue virus serotype 2
@en
type
label
Lovastatin delays infection an ...... d with dengue virus serotype 2
@ast
Lovastatin delays infection an ...... d with dengue virus serotype 2
@en
prefLabel
Lovastatin delays infection an ...... d with dengue virus serotype 2
@ast
Lovastatin delays infection an ...... d with dengue virus serotype 2
@en
P2860
P50
P1433
P1476
Lovastatin delays infection an ...... d with dengue virus serotype 2
@en
P2093
Juan C Gallego-Gómez
Luis A Correa-Londoño
P2860
P304
P356
10.1371/JOURNAL.PONE.0087412
P577
2014-02-21T00:00:00Z